You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSulfasalazine
Accession NumberDB00795  (APRD00152, DB08518)
TypeSmall Molecule
GroupsApproved
DescriptionA drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Structure
Thumb
Synonyms
2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid
2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid
4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene
5-((P-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid
5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid
5-(P-(2-Pyridylsulfamyl)phenylazo)salicylic acid
Azopyrin
Azulfidine
Salazosulfapiridina
Salazosulfapyridine
Salazosulfapyridinum
Salicylazosulfapyridine
Sulfasalazin
Sulfasalazina
Sulfasalazine
Sulfasalazinum
External Identifiers
  • SSZ
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Azulfidinetablet500 mg/1oralPharmacia and Upjohn Company1950-06-20Not applicableUs
Azulfidine En-tabstablet, delayed release500 mg/1oralPharmacia and Upjohn Company1950-06-20Not applicableUs
Orb-sulfasalazine ECtablet (enteric-coated)500 mgoralOrbus Pharma IncNot applicableNot applicableCanada
PMS-sulfasalazine 500mg/tab USPtablet500 mgoralPharmascience Inc1984-12-31Not applicableCanada
PMS-sulfasalazine-E.C. Tab 500mgtablet (enteric-coated)500 mgoralPharmascience Inc1984-12-31Not applicableCanada
Ratio-sulfasalazine Entablet (enteric-coated)500 mgoralRatiopharm Inc Division Of Teva Canada Limited1986-12-312008-08-01Canada
Ratio-sulfasalazine Tab 500mgtablet500 mgoralRatiopharm Inc Division Of Teva Canada Limited1986-12-312008-08-01Canada
S.A.S. Enteric 500mgtablet (enteric-coated)500 mgoralIcn Canada Ltd.1979-12-312005-04-26Canada
Salazopyrin En-tabs 500 mgtablet (enteric-coated)500 mgoralPfizer Canada Inc1995-12-31Not applicableCanada
Salazopyrin Enema 3.0gm/100mlsuspension3 grectalKabi Pharmacia Canada Inc.1994-12-311996-09-10Canada
Salazopyrin Enema 3gm/100mlenema3 grectalPfizer Canada Inc1996-12-312006-08-02Canada
Salazopyrin Tab 500mgtablet500 mgoralPfizer Canada Inc1995-12-31Not applicableCanada
Sas Enema 3gm/100mlenema3 grectalIcn Canada Ltd.1984-12-312005-04-26Canada
Sas Tab 500mgtablet500 mgoralIcn Canada Ltd.1973-12-312005-04-26Canada
Sulfasalazinetablet, delayed release500 mg/1oralGreenstone LLC2005-05-05Not applicableUs
Sulfasalazinetablet500 mg/1oralAphena Pharma Solutions Tennessee, Llc2003-07-01Not applicableUs
Sulfasalazinetablet500 mg/1oralGreenstone LLC2003-07-01Not applicableUs
Sulfasalazinetablet500 mg/1oralA S Medication Solutions Llc2003-07-01Not applicableUs
Sulfasalazinetablet500 mg/1oralKAISER FOUNDATION HOSPITALS2015-04-07Not applicableUs
Sulfasalazinetablet500 mg/1oralA S Medication Solutions Llc2003-07-01Not applicableUs
Sulfasalazinetablet500 mg/1oralMajor Pharmaceuticals2000-08-18Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Sulfasalazine Tab 500mgtablet500 mgoralApotex Inc1978-12-31Not applicableCanada
Sulfasalazinetablet500 mg/1oralREMEDYREPACK INC.2011-12-01Not applicableUs
Sulfasalazinetablet500 mg/1oralWatson Laboratories, Inc.1982-10-01Not applicableUs
Sulfasalazinetablet500 mg/1oralPreferred Pharmaceuticals, Inc2010-06-09Not applicableUs
Sulfasalazinetablet500 mg/1oralAidarex Pharmaceuticals LLC2002-01-11Not applicableUs
Sulfasalazinetablet500 mg/1oralAv Pak2014-01-14Not applicableUs
Sulfasalazinetablet500 mg/1oralQualitest Pharmaceuticals2002-01-11Not applicableUs
Sulfasalazinetablet500 mg/1oralREMEDYREPACK INC.2010-11-15Not applicableUs
Sulfasalazinetablet500 mg/1oralREMEDYREPACK INC.2013-05-15Not applicableUs
Sulfasalazinetablet500 mg/1oralREMEDYREPACK INC.2011-04-19Not applicableUs
Sulfasalazinetablet500 mg/1oralPd Rx Pharmaceuticals, Inc.2002-01-11Not applicableUs
Sulfasalazinetablet500 mg/1oralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs
Sulfasalazine Delayed-releasetablet, delayed release500 mg/1oralQualitest Pharmaceuticals2002-01-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AsasurfanChoseido Pharmaceutical
AzulfdidinaPfizer
AzulfinApsen
BomeconFu Seng
Colo-PleonSanofi-Aventis
DisalazinAC Farma
EminapyrinTaiyo Pharmaceutical
FlogostopIvax
IwataCadila
LanofenTaisho Yakuhin
LazafinNovell
PleonSanofi-Aventis
Pyralin ENPfizer
ReumazinAristopharma
SaazIpca
Saaz-DSIpca
SalasopyrineUpjohn
SalazarCadila
SalazidinHelcor
SalazineOpsonin
SalazopirinaJaba Recordati
SalazoprinCazi
SalazopyrinPfizer
Salazopyrin ENPfizer
Salazopyrin EN-TabsPharmacia
SulcolonBernofarm
SulfacolDrug International
WeiliufenSunve
ZopyrinHan Lim
Brand mixturesNot Available
SaltsNot Available
Categories
UNII3XC8GUZ6CB
CAS number599-79-1
WeightAverage: 398.393
Monoisotopic: 398.068490268
Chemical FormulaC18H14N4O5S
InChI KeyInChIKey=NCEXYHBECQHGNR-QZQOTICOSA-N
InChI
InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+
IUPAC Name
2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid
SMILES
OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as azobenzenes. These are organonitrogen aromatic compounds that contain a central azo group, where each nitrogen atom is conjugated to a bezene ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzobenzenes
Sub ClassNot Available
Direct ParentAzobenzenes
Alternative Parents
Substituents
  • Azobenzene
  • Salicylic acid
  • Salicylic acid or derivatives
  • Hydroxybenzoic acid
  • Benzenesulfonamide
  • Benzoic acid
  • Benzoic acid or derivatives
  • Benzoyl
  • Phenol
  • Aminopyridine
  • Imidolactam
  • Benzenoid
  • Pyridine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous acid
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azo compound
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
PharmacodynamicsSulfasalazine is an anti-inflammatory indicated for the treatment of ulcerative colitis and rheumatoid arthritis.
Mechanism of actionThe mode of action of Sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and in vitro models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of Sulfasalazine, SP and 5-ASA have indicated that the major therapeutic action may reside in the 5-ASA moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 7.5 ± 1.6 L
Protein bindingNot Available
MetabolismNot Available
Route of eliminationThe majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl-5-ASA with the feces.
Half life5-10 hours
Clearance
  • 1 L/h [IV administration]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier-0.7294
Caco-2 permeable-0.6893
P-glycoprotein substrateNon-substrate0.8405
P-glycoprotein inhibitor INon-inhibitor0.9096
P-glycoprotein inhibitor IINon-inhibitor0.853
Renal organic cation transporterNon-inhibitor0.8956
CYP450 2C9 substrateNon-substrate0.6445
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7557
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.923
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8895
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.6468
BiodegradationNot ready biodegradable0.9472
Rat acute toxicity1.4383 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.939
hERG inhibition (predictor II)Non-inhibitor0.821
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • Solvay pharmaceuticals
  • Heritage pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Superpharm corp
Packagers
Dosage forms
FormRouteStrength
Tabletoral500 mg/1
Tablet, delayed releaseoral500 mg/1
Tablet (enteric-coated)oral500 mg
Suspensionrectal3 g
Enemarectal3 g
Tabletoral500 mg
Prices
Unit descriptionCostUnit
Sulfasalazine powder2.14USD g
Azulfidine EN-tabs 500 mg Enteric Coated Tabs0.73USD tab
Azulfidine entab 500 mg0.69USD tablet
Azulfidine 500 mg tablet0.59USD tablet
Salazopyrin En-Tabs 500 mg Enteric-Coated Tablet0.45USD tablet
Sulfasalazine 500 mg Enteric Coated Tabs0.4USD tab
Pms-Sulfasalazine 500 mg Enteric-Coated Tablet0.34USD tablet
Salazopyrin 500 mg Tablet0.28USD tablet
Sulfasalazine 500 mg tablet0.25USD tablet
Sulfazine 500 mg tablet0.25USD tablet
Pms-Sulfasalazine 500 mg Tablet0.22USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point220 dec °CPhysProp
logP2.5Not Available
Caco2 permeability-6.33ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0464 mg/mLALOGPS
logP2.92ALOGPS
logP3.94ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)3.3ChemAxon
pKa (Strongest Basic)2.4ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area141.31 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity104.6 m3·mol-1ChemAxon
Polarizability39.69 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesA07EC01
AHFS Codes
  • 08:12.20
PDB EntriesNot Available
FDA labelDownload (796 KB)
MSDSDownload (72.8 KB)
Interactions
Drug Interactions
Drug
AbciximabSulfasalazine may increase the anticoagulant activities of Abciximab.
AcebutololSulfasalazine may decrease the antihypertensive activities of Acebutolol.
AceclofenacAceclofenac may increase the nephrotoxic activities of Sulfasalazine.
AceclofenacThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Aceclofenac.
AcenocoumarolSulfasalazine may increase the anticoagulant activities of Acenocoumarol.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Sulfasalazine.
Acetylsalicylic acidAcetylsalicylic acid may increase the nephrotoxic activities of Sulfasalazine.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Acetylsalicylic acid.
AdapaleneAdapalene may increase the nephrotoxic activities of Sulfasalazine.
AdapaleneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Adapalene.
Alendronic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alendronic acid.
AliskirenSulfasalazine may decrease the antihypertensive activities of Aliskiren.
AlprenololSulfasalazine may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Sulfasalazine.
AmikacinSulfasalazine may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideSulfasalazine may decrease the antihypertensive activities of Amiloride.
AncrodSulfasalazine may increase the anticoagulant activities of Ancrod.
AntipyrineAntipyrine may increase the nephrotoxic activities of Sulfasalazine.
AntipyrineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Antipyrine.
Antithrombin III humanSulfasalazine may increase the anticoagulant activities of Antithrombin III human.
ApixabanSulfasalazine may increase the anticoagulant activities of Apixaban.
ApremilastApremilast may increase the nephrotoxic activities of Sulfasalazine.
ApremilastThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Apremilast.
ArdeparinSulfasalazine may increase the anticoagulant activities of Ardeparin.
ArgatrobanSulfasalazine may increase the anticoagulant activities of Argatroban.
ArotinololSulfasalazine may decrease the antihypertensive activities of Arotinolol.
AtenololSulfasalazine may decrease the antihypertensive activities of Atenolol.
AzapropazoneAzapropazone may increase the nephrotoxic activities of Sulfasalazine.
AzapropazoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Azapropazone.
AzathioprineThe metabolism of Azathioprine can be decreased when combined with Sulfasalazine.
AzelastineAzelastine may increase the nephrotoxic activities of Sulfasalazine.
AzelastineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sulfasalazine.
BalsalazideSulfasalazine may increase the nephrotoxic activities of Balsalazide.
BecaplerminSulfasalazine may increase the anticoagulant activities of Becaplermin.
BefunololSulfasalazine may decrease the antihypertensive activities of Befunolol.
BemiparinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Bemiparin.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Sulfasalazine.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Sulfasalazine.
BenoxaprofenBenoxaprofen may increase the nephrotoxic activities of Sulfasalazine.
BenoxaprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Benoxaprofen.
BetaxololSulfasalazine may decrease the antihypertensive activities of Betaxolol.
BevantololSulfasalazine may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Sulfasalazine.
BisoprololSulfasalazine may decrease the antihypertensive activities of Bisoprolol.
BivalirudinSulfasalazine may increase the anticoagulant activities of Bivalirudin.
BopindololSulfasalazine may decrease the antihypertensive activities of Bopindolol.
BromfenacBromfenac may increase the nephrotoxic activities of Sulfasalazine.
BromfenacThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Bromfenac.
BufuralolSulfasalazine may decrease the antihypertensive activities of Bufuralol.
BumetanideSulfasalazine may decrease the diuretic activities of Bumetanide.
BupranololSulfasalazine may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Sulfasalazine.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Sulfasalazine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Sulfasalazine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Sulfasalazine.
CarprofenCarprofen may increase the nephrotoxic activities of Sulfasalazine.
CarprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Carprofen.
CarteololSulfasalazine may decrease the antihypertensive activities of Carteolol.
CarvedilolSulfasalazine may decrease the antihypertensive activities of Carvedilol.
CastanospermineCastanospermine may increase the nephrotoxic activities of Sulfasalazine.
CastanospermineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Castanospermine.
CelecoxibCelecoxib may increase the nephrotoxic activities of Sulfasalazine.
CelecoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Celecoxib.
CeliprololSulfasalazine may decrease the antihypertensive activities of Celiprolol.
CertoparinSulfasalazine may increase the anticoagulant activities of Certoparin.
ChloroquineChloroquine may increase the nephrotoxic activities of Sulfasalazine.
ChloroquineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Chloroquine.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sulfasalazine.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Sulfasalazine.
CholestyramineCholestyramine can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sulfasalazine.
Citric AcidSulfasalazine may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clodronate.
ClonixinClonixin may increase the nephrotoxic activities of Sulfasalazine.
ClonixinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Sulfasalazine.
ColesevelamColesevelam can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineSulfasalazine may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneD-Limonene may increase the nephrotoxic activities of Sulfasalazine.
D-LimoneneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with D-Limonene.
Dabigatran etexilateSulfasalazine may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinSulfasalazine may increase the anticoagulant activities of Dalteparin.
DanaparoidSulfasalazine may increase the anticoagulant activities of Danaparoid.
DaunorubicinSulfasalazine may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Deferasirox.
DesirudinSulfasalazine may increase the anticoagulant activities of Desirudin.
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Sulfasalazine.
DesmopressinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfasalazine.
DextranSulfasalazine may increase the anticoagulant activities of Dextran.
Dextran 40Sulfasalazine may increase the anticoagulant activities of Dextran 40.
Dextran 70Sulfasalazine may increase the anticoagulant activities of Dextran 70.
Dextran 75Sulfasalazine may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Sulfasalazine.
DicoumarolSulfasalazine may increase the anticoagulant activities of Dicoumarol.
DiflunisalDiflunisal may increase the nephrotoxic activities of Sulfasalazine.
DiflunisalThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Diflunisal.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Sulfasalazine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Sulfasalazine.
DihydrostreptomycinSulfasalazine may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Sulfasalazine.
DoxorubicinSulfasalazine may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneSulfasalazine may increase the hyperkalemic activities of Drospirenone.
DroxicamDroxicam may increase the nephrotoxic activities of Sulfasalazine.
DroxicamThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Droxicam.
Edetic AcidSulfasalazine may increase the anticoagulant activities of Edetic Acid.
EdoxabanSulfasalazine may increase the anticoagulant activities of Edoxaban.
EltrombopagThe serum concentration of Sulfasalazine can be increased when it is combined with Eltrombopag.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Sulfasalazine.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sulfasalazine.
EnoxaparinSulfasalazine may increase the anticoagulant activities of Enoxaparin.
EpirizoleEpirizole may increase the nephrotoxic activities of Sulfasalazine.
EpirizoleThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Epirizole.
EpirubicinSulfasalazine may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneSulfasalazine may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Sulfasalazine.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sulfasalazine.
EsmololSulfasalazine may decrease the antihypertensive activities of Esmolol.
Etacrynic acidSulfasalazine may decrease the diuretic activities of Etacrynic acid.
EtanerceptEtanercept may increase the nephrotoxic activities of Sulfasalazine.
EtanerceptThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etanercept.
Ethyl biscoumacetateSulfasalazine may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etidronic acid.
EtodolacEtodolac may increase the nephrotoxic activities of Sulfasalazine.
EtodolacThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etodolac.
EtofenamateEtofenamate may increase the nephrotoxic activities of Sulfasalazine.
EtofenamateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etofenamate.
EtoricoxibEtoricoxib may increase the nephrotoxic activities of Sulfasalazine.
EtoricoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etoricoxib.
Evening primrose oilEvening primrose oil may increase the nephrotoxic activities of Sulfasalazine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Evening primrose oil.
exisulindexisulind may increase the nephrotoxic activities of Sulfasalazine.
exisulindThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with exisulind.
FenbufenFenbufen may increase the nephrotoxic activities of Sulfasalazine.
FenbufenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fenbufen.
FenoprofenFenoprofen may increase the nephrotoxic activities of Sulfasalazine.
FenoprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Sulfasalazine.
FlunixinFlunixin may increase the nephrotoxic activities of Sulfasalazine.
FlunixinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flunixin.
FlurbiprofenFlurbiprofen may increase the nephrotoxic activities of Sulfasalazine.
FlurbiprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flurbiprofen.
Folic AcidThe serum concentration of Folic Acid can be decreased when it is combined with Sulfasalazine.
Fondaparinux sodiumSulfasalazine may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Sulfasalazine.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sulfasalazine.
FramycetinSulfasalazine may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideSulfasalazine may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Sulfasalazine.
GentamicinSulfasalazine may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Haloperidol.
HeparinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Heparin.
HirulogSulfasalazine may increase the anticoagulant activities of Hirulog.
HMPL-004HMPL-004 may increase the nephrotoxic activities of Sulfasalazine.
HMPL-004The risk or severity of adverse effects can be increased when Sulfasalazine is combined with HMPL-004.
HydralazineSulfasalazine may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Sulfasalazine.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Sulfasalazine.
Hygromycin BSulfasalazine may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibandronate.
IbuprofenIbuprofen may increase the nephrotoxic activities of Sulfasalazine.
IbuprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibuprofen.
IbuproxamIbuproxam may increase the nephrotoxic activities of Sulfasalazine.
IbuproxamThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibuproxam.
IcatibantIcatibant may increase the nephrotoxic activities of Sulfasalazine.
IcatibantThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Icatibant.
IdarubicinSulfasalazine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Sulfasalazine.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Sulfasalazine.
IndenololSulfasalazine may decrease the antihypertensive activities of Indenolol.
IndomethacinIndomethacin may increase the nephrotoxic activities of Sulfasalazine.
IndomethacinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Indomethacin.
IndoprofenIndoprofen may increase the nephrotoxic activities of Sulfasalazine.
IndoprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sulfasalazine.
IsoxicamIsoxicam may increase the nephrotoxic activities of Sulfasalazine.
IsoxicamThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Isoxicam.
KanamycinSulfasalazine may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneKebuzone may increase the nephrotoxic activities of Sulfasalazine.
KebuzoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Kebuzone.
KetoprofenKetoprofen may increase the nephrotoxic activities of Sulfasalazine.
KetoprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Sulfasalazine.
LabetalolSulfasalazine may decrease the antihypertensive activities of Labetalol.
LeflunomideLeflunomide may increase the nephrotoxic activities of Sulfasalazine.
LeflunomideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Leflunomide.
LepirudinSulfasalazine may increase the anticoagulant activities of Lepirudin.
LevobunololSulfasalazine may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Sulfasalazine.
LithiumThe serum concentration of Lithium can be increased when it is combined with Sulfasalazine.
LornoxicamLornoxicam may increase the nephrotoxic activities of Sulfasalazine.
LornoxicamThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Sulfasalazine.
LoxoprofenLoxoprofen may increase the nephrotoxic activities of Sulfasalazine.
LoxoprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Sulfasalazine.
LumiracoxibLumiracoxib may increase the nephrotoxic activities of Sulfasalazine.
LumiracoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Lumiracoxib.
Magnesium salicylateMagnesium salicylate may increase the nephrotoxic activities of Sulfasalazine.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Magnesium salicylate.
MasoprocolMasoprocol may increase the nephrotoxic activities of Sulfasalazine.
MasoprocolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Masoprocol.
MecamylamineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mecamylamine.
Meclofenamic acidMeclofenamic acid may increase the nephrotoxic activities of Sulfasalazine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Meclofenamic acid.
Mefenamic acidMefenamic acid may increase the nephrotoxic activities of Sulfasalazine.
Mefenamic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mefenamic acid.
MeloxicamMeloxicam may increase the nephrotoxic activities of Sulfasalazine.
MeloxicamThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Meloxicam.
MercaptopurineThe metabolism of Mercaptopurine can be decreased when combined with Sulfasalazine.
MesalazineMesalazine may increase the nephrotoxic activities of Sulfasalazine.
MetamizoleMetamizole may increase the nephrotoxic activities of Sulfasalazine.
MetamizoleThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Metamizole.
MethotrexateSulfasalazine may increase the hepatotoxic activities of Methotrexate.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sulfasalazine.
MetipranololSulfasalazine may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Sulfasalazine.
MetoprololSulfasalazine may decrease the antihypertensive activities of Metoprolol.
MetrizamideSulfasalazine may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Sulfasalazine.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Sulfasalazine.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Sulfasalazine.
Mycophenolate mofetilMycophenolate mofetil may increase the nephrotoxic activities of Sulfasalazine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mycophenolate mofetil.
Mycophenolic acidMycophenolic acid may increase the nephrotoxic activities of Sulfasalazine.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mycophenolic acid.
NabumetoneNabumetone may increase the nephrotoxic activities of Sulfasalazine.
NabumetoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nabumetone.
NadololSulfasalazine may decrease the antihypertensive activities of Nadolol.
NadroparinSulfasalazine may increase the anticoagulant activities of Nadroparin.
NaftifineNaftifine may increase the nephrotoxic activities of Sulfasalazine.
NaftifineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Naftifine.
NaproxenNaproxen may increase the nephrotoxic activities of Sulfasalazine.
NaproxenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Naproxen.
NCX 4016NCX 4016 may increase the nephrotoxic activities of Sulfasalazine.
NCX 4016The risk or severity of adverse effects can be increased when Sulfasalazine is combined with NCX 4016.
NeomycinSulfasalazine may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacNepafenac may increase the nephrotoxic activities of Sulfasalazine.
NepafenacThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nepafenac.
NetilmicinSulfasalazine may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidNiflumic Acid may increase the nephrotoxic activities of Sulfasalazine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Niflumic Acid.
NimesulideNimesulide may increase the nephrotoxic activities of Sulfasalazine.
NimesulideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sulfasalazine.
OlopatadineOlopatadine may increase the nephrotoxic activities of Sulfasalazine.
OlopatadineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Olopatadine.
OlsalazineSulfasalazine may increase the nephrotoxic activities of Olsalazine.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Sulfasalazine.
OrgoteinOrgotein may increase the nephrotoxic activities of Sulfasalazine.
OrgoteinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Orgotein.
OtamixabanSulfasalazine may increase the anticoagulant activities of Otamixaban.
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Sulfasalazine.
OxaprozinOxaprozin may increase the nephrotoxic activities of Sulfasalazine.
OxaprozinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Oxaprozin.
OxprenololSulfasalazine may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneOxyphenbutazone may increase the nephrotoxic activities of Sulfasalazine.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pamidronate.
ParecoxibParecoxib may increase the nephrotoxic activities of Sulfasalazine.
ParecoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Parecoxib.
ParnaparinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Parnaparin.
ParomomycinSulfasalazine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Sulfasalazine.
PenbutololSulfasalazine may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateSulfasalazine may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Sulfasalazine.
PhenindioneSulfasalazine may increase the anticoagulant activities of Phenindione.
PhenprocoumonSulfasalazine may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazonePhenylbutazone may increase the nephrotoxic activities of Sulfasalazine.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Phenylbutazone.
PimecrolimusPimecrolimus may increase the nephrotoxic activities of Sulfasalazine.
PimecrolimusThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pimecrolimus.
PindololSulfasalazine may decrease the antihypertensive activities of Pindolol.
PiretanideSulfasalazine may decrease the diuretic activities of Piretanide.
PirfenidonePirfenidone may increase the nephrotoxic activities of Sulfasalazine.
PirfenidoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pirfenidone.
PiroxicamPiroxicam may increase the nephrotoxic activities of Sulfasalazine.
PiroxicamThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Piroxicam.
PlicamycinSulfasalazine may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Sulfasalazine.
PractololSulfasalazine may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Sulfasalazine.
ProbenecidThe serum concentration of Sulfasalazine can be increased when it is combined with Probenecid.
PropacetamolPropacetamol may increase the nephrotoxic activities of Sulfasalazine.
PropacetamolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Propacetamol.
PropranololSulfasalazine may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Sulfasalazine.
Protein CSulfasalazine may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeSulfasalazine may increase the anticoagulant activities of Protocatechualdehyde.
PTC299PTC299 may increase the nephrotoxic activities of Sulfasalazine.
PTC299The risk or severity of adverse effects can be increased when Sulfasalazine is combined with PTC299.
PuromycinSulfasalazine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Sulfasalazine.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Sulfasalazine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Sulfasalazine.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Sulfasalazine.
ResveratrolResveratrol may increase the nephrotoxic activities of Sulfasalazine.
ResveratrolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Resveratrol.
ReviparinSulfasalazine may increase the anticoagulant activities of Reviparin.
RibostamycinSulfasalazine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Risedronate.
RivaroxabanSulfasalazine may increase the anticoagulant activities of Rivaroxaban.
RofecoxibRofecoxib may increase the nephrotoxic activities of Sulfasalazine.
RofecoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Rofecoxib.
RolapitantThe serum concentration of Sulfasalazine can be increased when it is combined with Rolapitant.
SalicylamideSalicylamide may increase the nephrotoxic activities of Sulfasalazine.
SalicylamideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Salicylamide.
Salicylic acidSalicylic acid may increase the nephrotoxic activities of Sulfasalazine.
Salicylic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Salicylic acid.
SalsalateSalsalate may increase the nephrotoxic activities of Sulfasalazine.
SalsalateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Sulfasalazine.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Sulfasalazine.
SeratrodastSeratrodast may increase the nephrotoxic activities of Sulfasalazine.
SeratrodastThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Seratrodast.
SotalolSulfasalazine may decrease the antihypertensive activities of Sotalol.
SpectinomycinSulfasalazine may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Sulfasalazine.
SpironolactoneSulfasalazine may decrease the antihypertensive activities of Spironolactone.
SRT501SRT501 may increase the nephrotoxic activities of Sulfasalazine.
SRT501The risk or severity of adverse effects can be increased when Sulfasalazine is combined with SRT501.
StreptomycinSulfasalazine may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinSulfasalazine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulindacSulindac may increase the nephrotoxic activities of Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Sulindac.
SulodexideSulfasalazine may increase the anticoagulant activities of Sulodexide.
SuprofenSuprofen may increase the nephrotoxic activities of Sulfasalazine.
SuprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Suprofen.
TacrolimusSulfasalazine may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Sulfasalazine.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Sulfasalazine.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sulfasalazine.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Sulfasalazine.
TenofovirThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tenofovir.
TenoxicamTenoxicam may increase the nephrotoxic activities of Sulfasalazine.
TenoxicamThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tenoxicam.
TepoxalinTepoxalin may increase the nephrotoxic activities of Sulfasalazine.
TepoxalinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tepoxalin.
TeriflunomideThe serum concentration of Sulfasalazine can be increased when it is combined with Teriflunomide.
TeriflunomideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Teriflunomide.
Tiaprofenic acidTiaprofenic acid may increase the nephrotoxic activities of Sulfasalazine.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tiaprofenic acid.
TiludronateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tiludronate.
TimololSulfasalazine may decrease the antihypertensive activities of Timolol.
TinzaparinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tinzaparin.
TioguanineThe metabolism of Tioguanine can be decreased when combined with Sulfasalazine.
TobramycinSulfasalazine may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidTolfenamic Acid may increase the nephrotoxic activities of Sulfasalazine.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tolfenamic Acid.
TolmetinTolmetin may increase the nephrotoxic activities of Sulfasalazine.
TolmetinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tolmetin.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Sulfasalazine.
TorasemideSulfasalazine may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Sulfasalazine.
TranilastTranilast may increase the nephrotoxic activities of Sulfasalazine.
TranilastThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Sulfasalazine.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Sulfasalazine.
TriamtereneSulfasalazine may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Sulfasalazine.
Trisalicylate-cholineTrisalicylate-choline may increase the nephrotoxic activities of Sulfasalazine.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Trisalicylate-choline.
ValdecoxibValdecoxib may increase the nephrotoxic activities of Sulfasalazine.
ValdecoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Valdecoxib.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Sulfasalazine.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Sulfasalazine.
WarfarinSulfasalazine may increase the anticoagulant activities of Warfarin.
XimelagatranSulfasalazine may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenZaltoprofen may increase the nephrotoxic activities of Sulfasalazine.
ZaltoprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Zaltoprofen.
ZileutonZileuton may increase the nephrotoxic activities of Sulfasalazine.
ZileutonThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Zileuton.
Zoledronic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Zoledronic acid.
ZomepiracZomepirac may increase the nephrotoxic activities of Sulfasalazine.
ZomepiracThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Zomepirac.
Food Interactions
  • May take Vitamin D.
  • Take with a full glass of water No iron, zinc or fluoride within 2 hours of taking this medication.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Iron ion binding
Specific Function:
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name:
ALOX5
Uniprot ID:
P09917
Molecular Weight:
77982.595 Da
References
  1. Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987 Jun;32(6):577-82. [PubMed:2882965 ]
  2. Allgayer H, Eisenburg J, Paumgartner G: Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol. 1984;26(4):449-51. [PubMed:6428914 ]
  3. Sircar JC, Schwender CF, Carethers ME: Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170-2. [PubMed:6131674 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8. [PubMed:14742690 ]
  2. Generini S, Fiori G, Matucci Cerinic M: Therapy of spondylarthropathy in inflammatory bowel disease. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94. [PubMed:12463455 ]
  3. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S: 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006 Oct;319(1):447-58. Epub 2006 Jul 19. [PubMed:16855178 ]
  4. Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002 Jul;46(1):1-6. [PubMed:12208114 ]
  5. Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7. [PubMed:9256165 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation...
Gene Name:
PPARG
Uniprot ID:
P37231
Molecular Weight:
57619.58 Da
References
  1. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005 Apr 18;201(8):1205-15. Epub 2005 Apr 11. [PubMed:15824083 ]
  2. Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O, Stein J: PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis. 2008 Jul;29(7):1407-14. doi: 10.1093/carcin/bgn118. Epub 2008 Jun 9. [PubMed:18544567 ]
  3. Linard C, Gremy O, Benderitter M: Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008 Mar;324(3):911-20. Epub 2007 Dec 12. [PubMed:18077625 ]
  4. Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9. [PubMed:16939423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications...
Gene Name:
CHUK
Uniprot ID:
O15111
Molecular Weight:
84638.88 Da
References
  1. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18. [PubMed:11054378 ]
  2. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These mo...
Gene Name:
IKBKB
Uniprot ID:
O14920
Molecular Weight:
86563.245 Da
References
  1. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18. [PubMed:11054378 ]
  2. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Cystine:glutamate antiporter activity
Specific Function:
Sodium-independent, high-affinity exchange of anionic amino acids with high specificity for anionic form of cystine and glutamate.
Gene Name:
SLC7A11
Uniprot ID:
Q9UPY5
Molecular Weight:
55422.44 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Gout PW, Buckley AR, Simms CR, Bruchovsky N: Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia. 2001 Oct;15(10):1633-40. [PubMed:11587223 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Plays a major role in ketone body metabolism.
Gene Name:
ACAT1
Uniprot ID:
P24752
Molecular Weight:
45199.2 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Faison LD, White HL: Sulfasalazine inhibits lyso-PAF: acetyl-COA acetyltransferase. Prostaglandins. 1992 Sep;44(3):245-9. [PubMed:1357724 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thromboxane-a synthase activity
Specific Function:
Not Available
Gene Name:
TBXAS1
Uniprot ID:
P24557
Molecular Weight:
60517.69 Da
References
  1. Stenson WF, Lobos E: Inhibition of platelet thromboxane synthetase by sulfasalazine. Biochem Pharmacol. 1983 Jul 15;32(14):2205-9. [PubMed:6135423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor binding
Specific Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides, this releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules.
Gene Name:
PLA2G1B
Uniprot ID:
P04054
Molecular Weight:
16359.535 Da
References
  1. Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7. [PubMed:9256165 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB: High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. Drug Metab Dispos. 2010 Apr;38(4):705-14. doi: 10.1124/dmd.109.028886. Epub 2010 Jan 13. [PubMed:20071452 ]
  2. Shukla S, Zaher H, Hartz A, Bauer B, Ware JA, Ambudkar SV: Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7. doi: 10.1007/s11095-008-9735-8. Epub 2008 Oct 9. [PubMed:18841445 ]
  3. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Methotrexate transporter activity
Specific Function:
Has been shown to act both as an intestinal proton-coupled high-affinity folate transporter and as an intestinal heme transporter which mediates heme uptake from the gut lumen into duodenal epithelial cells. The iron is then released from heme and may be transported into the bloodstream. Dietary heme iron is an important nutritional source of iron. Shows a higher affinity for folate than heme.
Gene Name:
SLC46A1
Uniprot ID:
Q96NT5
Molecular Weight:
49770.04 Da
References
  1. Nakai Y, Inoue K, Abe N, Hatakeyama M, Ohta KY, Otagiri M, Hayashi Y, Yuasa H: Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther. 2007 Aug;322(2):469-76. Epub 2007 May 2. [PubMed:17475902 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23